Evidence map›Paper›PMID 30201008›Full record

ArticleRetrovirology2018

Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.

Diogo Gama Caetano, Fernanda Heloise Côrtes, Gonzalo Bello, Sylvia Lopes Maia Teixeira, Brenda Hoagland, Beatriz Grinsztejn, Valdilea Gonçalves Veloso, Monick Lindenmeyer Guimarães, Mariza Gonçalves Morgado

Open access · goldAbstract readComparative Study
In one paragraph

Article in Retrovirology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Diogo Gama CaetanoLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Fernanda Heloise CôrtesLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Gonzalo BelloLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Sylvia Lopes Maia TeixeiraLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Brenda HoaglandLaboratório de Pesquisa Clínica em DST e Aids, Instituto Nacional de Infectologia Evandro Chagas (INI)-FIOCRUZ, Rio de Janeiro, Brazil.
Beatriz GrinsztejnLaboratório de Pesquisa Clínica em DST e Aids, Instituto Nacional de Infectologia Evandro Chagas (INI)-FIOCRUZ, Rio de Janeiro, Brazil.
Valdilea Gonçalves VelosoLaboratório de Pesquisa Clínica em DST e Aids, Instituto Nacional de Infectologia Evandro Chagas (INI)-FIOCRUZ, Rio de Janeiro, Brazil.
Monick Lindenmeyer GuimarãesLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil.
Mariza Gonçalves MorgadoLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz -FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ, 21045-900, Brazil. mmorgado@ioc.fiocruz.br.
Fundação Oswaldo Cruz · BRInstituto Evandro Chagas · BR

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic DiseaseR01EY026103 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2016 to 2019
$1.5M
Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq 305592/2010-6Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq 480875/2010-3Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ E-26/102.881/2008Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ E-26/103.095/2011NIAID NIH HHS UM1 AI069476
6 · The paper itself

Abstract

backgroundDespite the low level of viral replication in HIV controllers (HICs), studies have reported viral mutations related to escape from cytotoxic T-lymphocyte (CTL) response in HIV-1 plasma sequences. Thus, evaluating the dynamics of the emergence of CTL-escape mutants in HICs reservoirs is important for understanding viremia control. To analyze the HIV-1 mutational profile and dynamics of CTL-escape mutants in HICs, we selected 11 long-term non-progressor individuals and divided them into the following groups: (1) viremic controllers (VCs; n = 5) and (2) elite controllers (ECs; n = 6). For each individual, we used HIV-1 proviral DNA from PBMCs related to earliest (V

resultsDivergence analysis showed higher values for nef compared to gag among the HICs. EC and VC groups showed similar divergence rates for both genes. Analysis of the number of SNPs showed that VCs present more variability in both genes. Synonymous/non-synonymous mutation ratios were < 1 for gag among ECs and for nef among ECs and VCs, exhibiting a predominance of non-synonymous mutations. Such mutations were observed in regions encoding CTL-restricted epitopes in all individuals. All ECs presented non-synonymous mutations in CTL epitopes but generally at low frequency (< 1%); all VCs showed a high number of mutations, with significant frequency changes between V

conclusionsThe high genetic conservation of HIV-1 gag and nef among ECs indicates that the higher level of viremia control restricts the evolution of both genes. Although viral replication levels in HICs are low or undetectable, all individuals exhibited CTL epitope mutations in proviral gag and nef variants, indicating that potential CTL escape mutants are present in HIC reservoirs and that situations leading to a disequilibrium of the host-virus relationship can result in the spread of CTL-escape variants.

Indexed as

AdultAgedAged, 80 and overEpitopes, T-LymphocyteFemalegag Gene Products, Human Immunodeficiency VirusHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansMaleMiddle AgedMutationnef Gene Products, Human Immunodeficiency VirusPolymorphism, Single NucleotideProvirusesEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency Virusnef Gene Products, Human Immunodeficiency VirusCTL epitopeEscape mutantHIV-1HIV controllerNext-generation sequencingSingle-nucleotide polymorphism

Identifiers

PMID30201008
PMCPMC6131818
OpenAlexW2891511548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.